Annual treatment frequencies in all eyes. حسب Yasuyuki Sotani (20114144)

"…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…"

Annual number of outpatient visits in all eyes. حسب Yasuyuki Sotani (20114144)

"…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …"

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Annual treatment frequencies in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …"

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

"…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …"

Graphs showing the mean maximum temperature increase at the position with the highest mean temperature increase (A) and the mean temperature increase across all probes (B) for each... حسب Marsel Ganeyev (21453399)

Disruption of putative host factor LGMN decreases SARS-CoV-2 viral entry. حسب Ravi K. Dinesh (21736629)

Flow of premises through the study. حسب Eleni Mantzari (6991172)

"…After adjusting for prespecified covariates, the intervention resulted in a mean daily change of −2,769 ml (95% CI [−4,188, −1,578] <i>p</i> < 0.001) or −9.7% (95% CI [−13.5%, −6.1%] in beer sold. …"

Evolution from a single 20-year model simulation of a 5-year cycling strategy with DHA-PPQ used in the first five years, ASAQ in the following five years, AL during years 10-15, an... حسب Kien Trung Tran (12035464)

Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups. حسب Cristina Dolciotti (16317330)

Candidates from the RF method. The top 25 random forest candidates ranked by mean decrease in accuracy and mean decrease in Gini Index are in the first and second columns, respectively.... حسب Zoë Parker Cates (22184243)

"…The top 25 random forest candidates ranked by mean decrease in accuracy and mean decrease in Gini Index are in the first and second columns, respectively. …"

Demonstration of decreased Aβ accumulation by DA-9601 treatment. حسب Mijung Lee (397790)

CaMKKβ is involved in ST2-104-regulated decrease in autophagy. حسب Yingshi Ji (9013004)

CaMKKβ contributes to the decrease in apoptosis conferred by ST2-104. حسب Yingshi Ji (9013004)

Cardamonin induced apoptosis and decreased the MMP of ovarian cancer cells. حسب Peiguang Niu (17044532)

Graphs showing the mean temperature increase at the positions with the highest mean temperature increase for the MIPS (A) and MONO (B) systems and three drilling protocols (DP1, DP... حسب Marsel Ganeyev (21453399)

Five-stage speed adjustment. حسب Jianrong Cai (14245136)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: